News & Updates

Nirmatrelvir-ritonavir shows benefits in immunocompromised individuals with COVID-19

Effective antiviral therapy is crucial for achieving sustained viral clearance and improving outcomes in patients with COVID-19, particularly among immunocompromised individuals.

At the recent ESCMID Global 2025 in Vienna, Austria, Ruth Mokgokong, a pharmacologist at Pfizer, UK, presented findings from the EPIC-IC trial, highlighting the benefits of an extended nirmatrelvir-ritonavir regimen in severely immunocompromised patients with symptomatic COVID-19.

Point-of-care testing detects RTIs faster than ever

Respiratory tract infections (RTIs) have been on the rise post-COVID-19 pandemic.

Due to high patient volumes, delayed clinic presentations, and prolonged lead times for PCR testing in the laboratory, doctors need a rapid and accurate diagnostic tool to help improve in-clinic patient workflow.

Novel adaptor enhances care for patients on NIV

A new tube and inhaler adaptor (TIA) has been developed to improve the management of patients receiving noninvasive ventilation (NIV), and this device can be used across diverse clinical settings.

Depression tied to increased mortality in IPF

Patients with idiopathic pulmonary fibrosis (IPF) and comorbid depression are less likely to initiate antifibrotic treatment and thus face an increased risk of death, as reported in a study.

Nerandomilast safe, effective in autoimmune disease-related PPF

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

More cognitive issues, fewer heart problems after COVID-19 vs flu hospitalization in Asians

Individuals hospitalized for COVID-19 vs seasonal influenza face a greater risk of cognitive impairment and fatigue but a lower risk of cardiac disorders as long-term consequences of infection, according to a retrospective population-based cohort study in Singapore.

Wildfire smoke exposure ups risk of heart failure in older adults

Exposure to wildfire smoke for an extended period may increase the risk of heart failure (HF) in older adults, particularly women and socially vulnerable populations, suggests a study.

Short-course antibiotic for paediatric CAP on par with long-course regimen

A short-course antibiotic treatment for children with community-acquired pneumonia (CAP) demonstrates effectiveness similar to the long-course regimen but with fewer serious adverse events (AEs), reports a study.